Mustang Bio (MBIO) Earning Somewhat Positive Press Coverage, Analysis Finds

News coverage about Mustang Bio (NASDAQ:MBIO) has trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mustang Bio earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned headlines about the company an impact score of 48.6356422896574 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of Mustang Bio (NASDAQ:MBIO) opened at $10.43 on Tuesday. Mustang Bio has a 52 week low of $8.22 and a 52 week high of $13.35.

COPYRIGHT VIOLATION WARNING: “Mustang Bio (MBIO) Earning Somewhat Positive Press Coverage, Analysis Finds” was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at

About Mustang Bio

Mustang Bio, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market.

Receive News & Ratings for Mustang Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio Inc. and related companies with's FREE daily email newsletter.

Leave a Reply